BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bošnjak B, Odak I, Barros-Martins J, Sandrock I, Hammerschmidt SI, Permanyer M, Patzer GE, Greorgiev H, Gutierrez Jauregui R, Tscherne A, Schwarz JH, Kalodimou G, Ssebyatika G, Ciurkiewicz M, Willenzon S, Bubke A, Ristenpart J, Ritter C, Tuchel T, Meyer Zu Natrup C, Shin DL, Clever S, Limpinsel L, Baumgärtner W, Krey T, Volz A, Sutter G, Förster R. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. Front Immunol 2021;12:772240. [PMID: 34858430 DOI: 10.3389/fimmu.2021.772240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Schultz MD, Suschak JJ, Botta D, Silva-Sanchez A, King RG, Detchemendy TW, Meshram CD, Foote JB, Zhou F, Tipper JL, Zhang J, Harrod KS, Leal SM Jr, Randall TD, Roberts MS, Georges B, Lund FE. A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts. Hum Vaccin Immunother 2022;:2127292. [PMID: 36194255 DOI: 10.1080/21645515.2022.2127292] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Mura M, Simon F, Pommier de Santi V, Tangy F, Tournier JN. Role and Limits of COVID-19 Vaccines in the Delicate Transition from Pandemic Mitigation to Endemic Control. Vaccines (Basel) 2022;10:1555. [PMID: 36146633 DOI: 10.3390/vaccines10091555] [Reference Citation Analysis]
3 Orlova OV, Glazkova DV, Bogoslovskaya EV, Shipulin GA, Yudin SM. Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications. Vaccines 2022;10:1516. [DOI: 10.3390/vaccines10091516] [Reference Citation Analysis]
4 Pérez P, Astorgano D, Albericio G, Flores S, Sánchez-cordón PJ, Luczkowiak J, Delgado R, Casasnovas JM, Esteban M, García-arriaza J. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection. Front Immunol 2022;13:995235. [DOI: 10.3389/fimmu.2022.995235] [Reference Citation Analysis]
5 Young A. T cells in SARS-CoV-2 infection and vaccination. Ther Adv Vaccines Immunother 2022;10:25151355221115011. [PMID: 36051003 DOI: 10.1177/25151355221115011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Zhang M, Li N, He Y, Shi T, Jie Z. Pulmonary resident memory T cells in respiratory virus infection and their inspiration on therapeutic strategies. Front Immunol 2022;13:943331. [DOI: 10.3389/fimmu.2022.943331] [Reference Citation Analysis]
7 Mei S, Fan Z, Liu X, Zhao F, Huang Y, Wei L, Hu Y, Xie Y, Wang L, Ai B, Liang C, Xu F, Guo F. Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate. Front Immunol 2022;13:911164. [DOI: 10.3389/fimmu.2022.911164] [Reference Citation Analysis]
8 Seyran M. Artificial intelligence and clinical data suggest the T cell-mediated SARS-CoV-2 nonstructural protein intranasal vaccines for global COVID-19 immunity. Vaccine 2022:S0264-410X(22)00821-0. [PMID: 35778279 DOI: 10.1016/j.vaccine.2022.06.052] [Reference Citation Analysis]
9 Americo JL, Cotter CA, Earl PL, Liu R, Moss B. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection. Proc Natl Acad Sci U S A 2022;119:e2202069119. [PMID: 35679343 DOI: 10.1073/pnas.2202069119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
10 Du W, Hurdiss DL, Drabek D, Mykytyn AZ, Kaiser FK, González-Hernández M, Muñoz-Santos D, Lamers MM, van Haperen R, Li W, Drulyte I, Wang C, Sola I, Armando F, Beythien G, Ciurkiewicz M, Baumgärtner W, Guilfoyle K, Smits T, van der Lee J, van Kuppeveld FJM, van Amerongen G, Haagmans BL, Enjuanes L, Osterhaus ADME, Grosveld F, Bosch BJ. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern. Sci Immunol 2022;:eabp9312. [PMID: 35471062 DOI: 10.1126/sciimmunol.abp9312] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
11 Boudewijns R, Pérez P, Lázaro-Frías A, Van Looveren D, Vercruysse T, Thibaut HJ, Weynand B, Coelmont L, Neyts J, Astorgano D, Montenegro D, Puentes E, Rodríguez E, Dallmeier K, Esteban M, García-Arriaza J. MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters. Front Immunol 2022;13:845969. [PMID: 35371064 DOI: 10.3389/fimmu.2022.845969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Stoddard M, Novokhodko A, Sarkar S, Van Egeren D, White LF, Hochberg NS, Rogers M, Zetter B, Joseph-mccarthy D, Chakravarty A. Endemicity is not a victory: the unmitigated downside risks of widespread SARS-CoV-2 transmission.. [DOI: 10.1101/2022.03.29.22273146] [Reference Citation Analysis]
13 Du W, Hurdiss DL, Drabek D, Mykytyn AZ, Kaiser FK, González-hernandez M, Muñoz-santos D, Lamers MM, van Haperen R, Li W, Drulyte I, Wang C, Sola I, Armando F, Beythien G, Ciurkiewicz M, Baumgärtner W, Guilfoyle K, Smits T, van der Lee J, van Kuppeveld FJ, van Amerongen G, Haagmans BL, Enjuanes L, Osterhaus AD, Grosveld F, Bosch B. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants.. [DOI: 10.1101/2022.02.17.480751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]